Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 7/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.31 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108613 | 0.92 | MAPKAPK2 (0.38) | JMJD6MAPK14GRM2PFKFB3MAPKAPK2 | |
| SCHEMBL9110581 | 0.91 | MAPK14 (0.43) | JMJD6MAPK14 | |
| SCHEMBL9111940 | 0.91 | JMJD6 (0.33) | JMJD6MAPK14GRM2PFKFB3MAPKAPK2 | |
| SCHEMBL9111849 | 0.87 | MAPKAPK2 (0.43) | JMJD6MAPK14GRM2PFKFB3MAPKAPK2 | |
| SCHEMBL9905454 | 0.86 | JMJD6 (0.33) | JMJD6PFKFB3BRD4 | |
| SCHEMBL9108784 | 0.86 | MAPKAPK2 (0.43) | JMJD6MAPK14GRM2MAPKAPK2MAPKAPK5 | |
| SCHEMBL9111748 | 0.86 | MAPKAPK2 (0.39) | JMJD6MAPK14GRM2MAPKAPK2MAPKAPK5 | |
| SCHEMBL9112137 | 0.85 | MAPK14 (0.33) | MAPK14MAPKAPK2MAPKAPK5BRD4 | |
| SCHEMBL9110461 | 0.84 | MAPKAPK2 (0.45) | JMJD6MAPK14GRM2MAPKAPK2MAPKAPK5 | |
| SCHEMBL9111410 | 0.84 | NMT1 (0.33) | MAPK14MAPKAPK2MAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648516-B1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2018-09-05 | — | — | EP | claimed |
| US-9365547-B2 | Substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20140171450-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-06-19 | — | — | US | claimed |
| EP-2648516-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Confluence Life Sciences, Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| WO-2012078684-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | claimed |
| EP-3469907-B1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3469907-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2648516-B1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9365547-B2 | Substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365546-B2 | Substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140171450-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171449-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2648516-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Confluence Life Sciences, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078684-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171450-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | JMJD6 1228/4885MAPK14 47/4885GRM2 2327/4885 |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | JMJD6 1228/4885MAPK14 47/4885GRM2 2327/4885 |
| US-20140171449-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | JMJD6 1228/4885MAPK14 47/4885GRM2 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.